SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTII - Miscellaneous
NTII 0.00010000.0%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy8/17/2005 10:04:15 PM
   of 1296
 
2005 - Memantine for Migraine

Treatments Typically Used in Neurologic Settings: Memantine and Tiagabine
Two drugs typically used in the treatment of neurologic disease, memantine and tiagabine, show potential in 2 different pain settings -- migraine and fibromyalgia, respectively.[8,9] In the first study, Sorensen and Jenson[8] explored memantine, which is approved for the treatment of Alzheimer's disease, as a prophylactic agent for reducing the frequency of migraine. The 18 patients in the study had been refractory to a variety of other prophylactic agents and acute migraine therapies. However, 11 of the patients described their results as excellent and 4 as good. Sorensen[9] also investigated the anticonvulsant tiagabine as a treatment for primary fibromyalgia syndrome. The short-form of the McGill Pain Questionnaire was used. Again, the 11 patients had not responded to a variety of standard treatments, including opiates, NSAIDs, tricyclic antidepressants, and another anticonvulsant -- gabapentin. In this case, 6 patients reported an excellent result and 1 reported a good result, again with the McGill short form. One patient discontinued due to nausea and sedation, and 1 patient withdrew due to a poor response. Dr. Sorensen stressed that further investigation would be necessary with both therapies, although the initial results are promising

Sorensen R, Jenson MS. Memantine, a treatment for migraine: a prospective open-label trial. Program and abstracts of the 21st Annual Meeting of the American Academy of Pain Medicine; February 23-27, 2005; Palm Springs, California. Abstract 101.

medscape.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext